+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID03847649

Durvalumab Treatment Study in Cancer Patients After Immune Therapy Side Effects and Continued Treatment with or without Tremelimumab in Previous CCTG Trials

Led by Canadian Cancer Trials Group · Updated on 2026-09-15

60

Participants Needed

11

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the effects of durvalumab, an immunotherapy drug, on various types of advanced or metastatic solid tumors in patients who have previously stopped checkpoint therapy due to immune-related side effects. They are also evaluating whether prednisone, a steroid, can help reduce these side effects when given with durvalumab. Additionally, the study allows patients from completed Canadian Cancer Trials Group CCTG trials to continue treatment with durvalumab, with or without tremelimumab. Participants receive durvalumab intravenously every four weeks, with prednisone given orally during the first two cycles to assess its impact on side effects. Some patients may also continue treatment with tremelimumab alongside durvalumab, depending on their previous trial enrollment. The study includes two substudies one focusing on patients who discontinued prior immunotherapy due to toxicity, and another allowing continued treatment for those already enrolled in completed CCTG trials. Throughout the study, participants undergo regular monitoring including laboratory tests and imaging to track disease status and side effects. Researchers record the number and severity of adverse events over two years, as well as treatment responses and the effectiveness of corticosteroids in preventing immune-related side effects. Patients are followed closely for treatment safety and efficacy, with a minimum life expectancy of 12 weeks required for participation.

CONDITIONS

Brief Title

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Research Team

P

Pierre-Olivier Gaudreau

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here